[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Capitol Health Call
January 11, 2006

Scrutinizing ED Drugs

JAMA. 2006;295(2):152. doi:10.1001/jama.295.2.152-d

Senate Finance Committee Chairman Charles Grassley (R, Iowa) said the Food and Drug Administration (FDA) has taken important steps to inform consumers about the potential risk of vision loss associated with using drugs (sildenafil, tadalafil, and vardenafil) to treat erectile dysfunction (ED).

Last summer, the FDA approved updated labeling for these ED drugs to reflect some postmarketing reports of sudden vision loss attributed to nonarteritic ischemic optic neuropathy.

First Page Preview View Large
First page PDF preview
First page PDF preview